Chemical Name:Nilotinib

CAS No.: 641571-10-0

Molecular formula: C28H22F3N7O

Molecular weight: 529.52

Related categories: anti-tumor; APIs; intermediates; anticancer drugs; pharmaceutical intermediates;

Nature

Description

Nitroninib (Tasigna) is a novel targeted tumor therapy drug, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia (CML) resistant to Gleevec (imatinib). The patient has a significant effect.

Imatinib mesylate

Imatinib mesylate is a new generation of targeted anticancer drugs that inhibits platelet-derived growth factor (PDGF) receptor protein kinase and is the best of all antitumor drugs. The new diagnosis of chronic myelogenous leukemia (CML) is more than 94% effective, and 76% of patients can get cytological remission. The main indications are as follows:

1. Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase.

2. Treatment of Philadelphia chromosome-positive chronic myeloid leukemia in a blast phase and an accelerated phase.

3. Treatment of chronic myeloid leukemia in chronic phase that has been treated with interferon.

4. Treatment of pediatric chronic myelogenous leukemia with relapse after myelosuppression or ineffective treatment with interferon.

5. Treatment of KIT (CD117)-positive inoperable or metastatic malignant gastrointestinal stromal tumors.